Friday, March 27, 2026
30.3
C
Bengaluru
Hot topics
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
Indian Pharma Regional Performance Analysis & Summary
Overall Market Performance (IPM)• The Indian Pharmaceutical Market (IPM)...
A Social Experiment
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, RB Balakrishna and Rajiv Jayaraman
Glosing the Gender Gap
Guest Editorial by Sharadha Iyer on the urgent need to close the gender gap in the Indian Pharma Industry
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Hot topics
Pharma in the New Normal
2020 has been a challenging year for all industries. For pharma and its HCP customers even more so. All eyes are on the companies developing vaccines and drugs for treatment of COVID-19, while doctors have closed their doors for pharma reps. Long established processes have been disrupted and complex market strategies have been rendered useless. Each pharma no matter big or small, innovative, or generic, had to improvise and come up with contingency plans to save the year. Some have been slower waiting for the old ways to come back, others have been more agile experimenting with digital and expanding boundaries, most are in the middle digitally curious but not risking too much.
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
MedicinMan Steps into Year Five
Articles by K. Hariram, Daxesh Patel, Gopal Kishore, Amit Jain, Sunil Bajaj and Vivek Hattangadi
Culture and Resistance to Change – A Pharma SFE Adoption Case Study
As an MNC Head, I was one among the...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Newsletter
Get important news delivered directly to your inbox and stay connected!